Stevens Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Stevens Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-16,117	Closed	-$165K	–	1225
2016 Q3	$165K	Buy	16,117 +4,173	+35%	+$45.5K	0.01%	819
2016 Q2	$156K	Buy	+11,944	New	+$156K	0.01%	805
2016 Q1	–	Sell	-20,194	Closed	-$186K	–	1232
2015 Q4	$186K	Sell	20,194 -631	-3%	-$5.28K	0.01%	812
2015 Q3	$145K	Sell	20,825 -3,099	-13%	-$26.5K	0.01%	869
2015 Q2	$235K	Buy	+23,924	New	+$218K	0.01%	825
2014 Q2	–	Sell	-25,147	Closed	-$114K	–	1434
2014 Q1	$114K	Sell	25,147 -2,707	-10%	-$13.1K	﹤0.01%	1002
2013 Q4	$140K	Buy	27,854 +4,161	+18%	+$20K	﹤0.01%	949
2013 Q3	$120K	Sell	23,693 -15,003	-39%	-$83.5K	﹤0.01%	964
2013 Q2	$192K	Buy	+38,696	New	+$184K	0.01%	819

Other funds holding SCLN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Stevens Capital Management's SCLN Position: Q4 2016 in Review

Stevens Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 16,117 shares — an estimated $165K sold.

Stevens Capital Management first reported a position in SCLN in Q2 2013 and held it in 9 quarters. The position peaked at $235K in Q2 2015. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

Stevens Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
Stevens Capital Management sold 16,117 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $165K.
Stevens Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 9 quarters.
Stevens Capital Management's Sciclone Pharmaceuticals Inc position peaked at $235K in Q2 2015.
153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on Stevens Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.